Filing Details

Accession Number:
0001209191-21-061975
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-10-28 19:54:42
Reporting Period:
2021-10-26
Accepted Time:
2021-10-28 19:54:42
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1370053 Anaptysbio Inc ANAB Pharmaceutical Preparations (2834) 203828755
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1654495 Hamza Suria C/O Anaptysbio, Inc.
10770 Wateridge Circle, Suite 210
San Diego CA 92121
President, Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-10-26 15,993 $1.12 83,629 No 4 M Direct
Common Stock Disposition 2021-10-26 15,993 $30.00 67,636 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (right to buy) Disposition 2021-10-26 15,993 $0.00 15,993 $1.12
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
73,291 2022-01-31 No 4 M Direct
Footnotes
  1. The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
  2. The stock option grant was issued on January 31, 2012 and became fully vested as of January 31, 2016, and is exercisable until its expiration date of January 31, 2022.
  3. In addition to the remaining options to purchase 73,291 shares of common stock as set forth in Table II above, the Reporting Person also holds (i) additional options to purchase up to an aggregate of 1,139,254 shares of common stock, which options vest according to their terms, and (ii) 67,636 shares of common stock held directly.